CN103096909A - 与谷氨酰-脯氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 - Google Patents

与谷氨酰-脯氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 Download PDF

Info

Publication number
CN103096909A
CN103096909A CN2011800315491A CN201180031549A CN103096909A CN 103096909 A CN103096909 A CN 103096909A CN 2011800315491 A CN2011800315491 A CN 2011800315491A CN 201180031549 A CN201180031549 A CN 201180031549A CN 103096909 A CN103096909 A CN 103096909A
Authority
CN
China
Prior art keywords
aars
protein fragments
cell
seq
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800315491A
Other languages
English (en)
Chinese (zh)
Inventor
莱斯利·安·格林尼
凯尔·P·基昂格
洪非
阿兰·P·瓦瑟洛特
罗咏诗
杰弗里·D·沃特金斯
约翰·D·门德莱恩
谢丽尔·L·奎恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pangu Biopharma Ltd
aTyr Pharma Inc
Original Assignee
Pangu Biopharma Ltd
aTyr Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pangu Biopharma Ltd, aTyr Pharma Inc filed Critical Pangu Biopharma Ltd
Publication of CN103096909A publication Critical patent/CN103096909A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
CN2011800315491A 2010-05-04 2011-05-04 与谷氨酰-脯氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 Pending CN103096909A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US33108410P 2010-05-04 2010-05-04
US33128010P 2010-05-04 2010-05-04
US33126510P 2010-05-04 2010-05-04
US61/331,265 2010-05-04
US61/331,280 2010-05-04
US61/331,084 2010-05-04
PCT/US2011/035250 WO2011140266A2 (en) 2010-05-04 2011-05-04 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-trna synthetases

Publications (1)

Publication Number Publication Date
CN103096909A true CN103096909A (zh) 2013-05-08

Family

ID=44904460

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800315491A Pending CN103096909A (zh) 2010-05-04 2011-05-04 与谷氨酰-脯氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现

Country Status (7)

Country Link
US (3) US9062301B2 (enExample)
EP (1) EP2566492B1 (enExample)
JP (2) JP6008843B2 (enExample)
CN (1) CN103096909A (enExample)
AU (1) AU2011248100B2 (enExample)
CA (1) CA2798301C (enExample)
WO (1) WO2011140266A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110234757A (zh) * 2016-08-23 2019-09-13 韩国生命工学研究院 包含eprs蛋白或其片段的抗rna病毒组合物

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2552773T3 (es) 2009-02-27 2015-12-02 Atyr Pharma, Inc. Motivos estructurales de polipéptidos asociados con la actividad de señalización celular
CA2797093C (en) 2010-04-26 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
CA2797362C (en) 2010-04-27 2020-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
CA2797259C (en) 2010-04-27 2020-09-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl trna synthetases
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
EP2563383B1 (en) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
US8986680B2 (en) 2010-04-29 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
CA2797977C (en) 2010-05-03 2019-08-20 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
CN103140233B (zh) 2010-05-03 2017-04-05 Atyr 医药公司 与甲硫氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
WO2011139986A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
AU2011248357B2 (en) 2010-05-03 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases
EP2566499B1 (en) 2010-05-04 2017-01-25 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
US9062301B2 (en) 2010-05-04 2015-06-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-tRNA synthetases
CA2799197C (en) 2010-05-14 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
US9034598B2 (en) 2010-05-17 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
AU2011258106B2 (en) 2010-05-27 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
CN103118694B (zh) 2010-06-01 2016-08-03 Atyr医药公司 与赖氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
CA2804278C (en) 2010-07-12 2021-07-13 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases
JP6116479B2 (ja) 2010-07-12 2017-04-19 エータイアー ファーマ， インコーポレイテッド グリシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
EP2593126B1 (en) 2010-07-12 2017-09-20 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
JP5964304B2 (ja) 2010-08-25 2016-08-03 エータイアー ファーマ， インコーポレイテッド チロシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CA2812795C (en) 2010-10-06 2021-08-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl trna synthetases
US20160144003A1 (en) * 2011-05-19 2016-05-26 The Scripps Research Institute Compositions and methods for treating charcot-marie-tooth diseases and related neuronal diseases
WO2013022982A2 (en) 2011-08-09 2013-02-14 Atyr Pharma, Inc. Pegylated tyrosyl-trna synthetase polypeptides
US9816084B2 (en) 2011-12-06 2017-11-14 Atyr Pharma, Inc. Aspartyl-tRNA synthetases
WO2013086228A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Pegylated aspartyl-trna synthetase polypeptides
CN104220461A (zh) 2011-12-29 2014-12-17 Atyr医药公司 天冬氨酰-tRNA合成酶-FC缀合物
CN114717206A (zh) 2013-03-15 2022-07-08 Atyr 医药公司 组氨酰-trna合成酶-fc缀合物
ES2994451T3 (en) 2017-04-20 2025-01-24 Atyr Pharma Inc Compositions for treating lung inflammation
KR102338644B1 (ko) 2017-06-02 2021-12-13 닛폰세이테츠 가부시키가이샤 무방향성 전자 강판
WO2019055594A1 (en) 2017-09-13 2019-03-21 North Carolina State University BRUSHING ADIPOSE TISSUE INDUCED LOCALLY BY MICRO-NEEDLE STAMPS FOR THE TREATMENT OF OBESITY
CN114829590A (zh) * 2019-12-19 2022-07-29 延世大学校产学协力团 通过融合whep结构域来提高靶蛋白的水溶性的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1352242A (zh) * 2000-11-02 2002-06-05 上海博德基因开发有限公司 一种新的多肽——人谷氨酰tRNA合成酶12.65和编码这种多肽的多核苷酸
WO2004087730A2 (en) * 2003-03-27 2004-10-14 The Johns Hopkins University Method for producing diverse libraries of encoded polymers
US20050136513A1 (en) * 2003-12-18 2005-06-23 The Scripps Research Institute Selective incorporation of 5-hydroxytryptophan into proteins in mammalian cells
US7248971B1 (en) * 2000-11-14 2007-07-24 International Business Machines Corporation Method and apparatus for discovering patterns in a set of sequences
CN102239253A (zh) * 2008-12-03 2011-11-09 普罗蒂亚维仕尼科技有限公司 谷氨酰tRNA合成酶（GtS）片段

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9115660U1 (de) 1991-12-18 1992-07-30 Aventis Research & Technologies GmbH & Co KG, 65929 Frankfurt L-Phenylalanyl-tRNA-Synthetase mit erweiterter Substratselektivität aus Mikroorganismen
US5759833A (en) 1994-05-27 1998-06-02 Cubist Pharmaceuticals, Inc. Human isoleucyl-tRNA synthetase proteins, nucleic acids and tester strains comprising same
US5756327A (en) 1994-09-13 1998-05-26 Cubist Pharmaceuticals, Inc. Recombinant mycobacterial isoleucyl-tRNA synthetase genes, tester strains and assays
US5798240A (en) 1994-09-13 1998-08-25 Cubist Pharmaceuticals, Inc. Recombinant mycobacterial methionyl-tRNA synthetase genes and methods of use therefore
US5801013A (en) 1995-05-26 1998-09-01 Cubist Pharmaceuticals, Inc. Helicobacter aminoacyl-tRNA synthetase proteins, nucleic acids and strains comprising same
JP2001501447A (ja) 1996-01-11 2001-02-06 コリクサ コーポレイション 乳癌の処置および診断のための組成物および方法
US5750387A (en) 1996-01-19 1998-05-12 Smithkline Beecham P.L.C. DNA encoing leucyl TRNA synthetase from staphylococcus aureus
US5795757A (en) 1997-01-17 1998-08-18 Smithkline Beecham, P.L.C. DNA encoding threonyl tRNA synthetase from staphylococcus aureus
EP0785269A1 (en) 1996-01-19 1997-07-23 Smithkline Beecham Plc Histidyl-tRNA synthetase of Staphylococcus aureus
GB9601067D0 (en) 1996-01-19 1996-03-20 Smithkline Beecham Plc Novel compounds
GB9607993D0 (en) 1996-04-18 1996-06-19 Smithkline Beecham Plc Novel compounds
US5795758A (en) 1997-04-18 1998-08-18 Smithkline Beecham Corporation DNA encoding histidyl tRNA synthetase variant from Streptococcus pneumoniae
GB9607991D0 (en) 1996-04-18 1996-06-19 Smithkline Beecham Plc Novel compounds
KR100203919B1 (ko) 1996-10-04 1999-06-15 신동권 수용성 단백질을 생산하는 새로운 발현 플라스미드
US5885815A (en) 1996-11-01 1999-03-23 Cubist Pharmaceuticals, Inc. Candida isoleucyl-tRNA synthetase proteins, nucleic acids and strains comprising same
US5776749A (en) 1997-01-17 1998-07-07 Smithkline Beecham P.L.C. DNA encoding cysteinyl tRNA synthetase from Staphylococcus aureus
AU745787B2 (en) 1997-05-06 2002-03-28 Human Genome Sciences, Inc. Enterococcus faecalis polynucleotides and polypeptides
US5882892A (en) 1997-07-23 1999-03-16 Smithkline Beecham Corporation Asps
US5858720A (en) 1997-07-23 1999-01-12 Smithkline Beecham Corporation Hiss
US5939298A (en) 1997-07-23 1999-08-17 Smithkline Beecham Corporation DNA encoding phenylalanyl tRNA synthetase alpha sub-unit from chlamydi a trachomatis
AU2898299A (en) 1998-03-04 1999-09-20 Onyx Pharmaceuticals, Inc. Baculovirus expression system and method for high throughput expression of genetic material
US6428960B1 (en) 1998-03-04 2002-08-06 Onyx Pharmaceuticals, Inc. Selection method for producing recombinant baculovirus
US6255090B1 (en) 1998-07-15 2001-07-03 E. I. Du Pont De Nemours & Company Plant aminoacyl-tRNA synthetase
US6271441B1 (en) 1998-07-21 2001-08-07 E. I. Du Pont De Nemours & Company Plant aminoacyl-tRNA synthetase
US6696619B1 (en) 1998-11-05 2004-02-24 Omolayo O. Famodu Plant aminoacyl-tRNA synthetases
EP1200596A2 (en) 1999-07-22 2002-05-02 Incyte Genomics, Inc. Human synthetases
WO2001019999A1 (en) 1999-09-14 2001-03-22 Shanghai Biorigin Gene Development Co. Ltd. A GENE ENCODING A NOVEL THREONYL-tRNA SYNTHETASE, ITS USES AND THE PREPARING METHODS
US6548060B1 (en) 1999-11-18 2003-04-15 Sunghoon Kim Anti-apoptotic use of human glutaminyl-tRNA synthetase with two consecutive pro-apoptotic mediators
AU2001234944A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
CN1311300A (zh) 2000-03-02 2001-09-05 上海博德基因开发有限公司 一种新的多肽－人苏氨酰－tRNA合成酶14和编码这种多肽的多核苷酸
JP4868681B2 (ja) 2000-03-31 2012-02-01 ザ スクリプス リサーチ インスティチュート 血管新生の調節のために有用なヒトアミノアシル−ｔＲＮＡシンテターゼポリペプチド
US7273844B2 (en) 2000-03-31 2007-09-25 The Scripps Research Institute Tryptophanyl-tRNA synthetase-derived polypeptides useful for the regulation of angiogenesis
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7144984B2 (en) 2000-03-31 2006-12-05 The Scripps Research Institute Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
US20040181830A1 (en) 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
CN1322818A (zh) 2000-05-09 2001-11-21 上海博德基因开发有限公司 一种新的多肽——人II类氨酰基－tRNA合成酶10和编码这种多肽的多核苷酸
WO2001088188A2 (en) 2000-05-18 2001-11-22 Nihon University, School Juridical Person Method for examining ischemic conditions
JP2004510407A (ja) 2000-05-25 2004-04-08 インサイト・ゲノミックス・インコーポレイテッド アミノアシルｔＲＮＡ合成酵素
CN1341725A (zh) 2000-09-07 2002-03-27 上海博德基因开发有限公司 一种新的多肽——人苏氨酰－tRNA合成酶48.73和编码这种多肽的多核苷酸
CN1341727A (zh) 2000-09-07 2002-03-27 上海博德基因开发有限公司 一种新的多肽——甲硫氨酰tRNA合成酶35.09和编码这种多肽的多核苷酸
CN1352252A (zh) 2000-11-06 2002-06-05 上海博德基因开发有限公司 一种新的多肽——人II类氨酰基－tRNA合成酶11.77和编码这种多肽的多核苷酸
WO2002044349A2 (en) 2000-11-28 2002-06-06 Mcgill University INCORPORATION AND PRIMING FUNCTION OF tRNALYS IN HIV AND RELATED VIRUSES
EP1349939A2 (en) 2000-12-15 2003-10-08 Incyte Genomics, Inc. Aminoacyl trna synthetases
CN100486992C (zh) 2001-02-23 2009-05-13 斯克里普斯研究学院 用于调节血管发生的色氨酰-tRNA合成酶衍生的多肽
US6903189B2 (en) 2001-03-21 2005-06-07 The Scripps Research Institute Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
ES2464532T3 (es) 2001-04-19 2014-06-03 The Scripps Research Institute Métodos y composiciones para la producción de pares ortogonales de ARNt-aminoacil-ARNt sintetasa
US20030215827A1 (en) 2001-05-22 2003-11-20 Henry Yue Aminoacyl trna synthetases
KR100405919B1 (ko) 2001-06-05 2003-11-14 주식회사 이매진 ｐ43의 Ｎ-말단 펩타이드를 유효성분으로 하는 면역증강용 약학조성물
US20040018505A1 (en) 2001-06-29 2004-01-29 Lee Ernestine A. Aminoacyl trna synthetases
WO2003009813A2 (en) 2001-07-26 2003-02-06 Novartis Ag Methods of treating neuropilin-mediated diseases
US7785827B2 (en) 2001-09-20 2010-08-31 University Of Houston System Method and composition for leucyl-tRNA synthetases and derivatives thereof that activate and aminoacylate non-leucine amino acid to tRNA adaptor molecules
US20040048290A1 (en) 2001-12-13 2004-03-11 Lee Ernestine A Aminoacyl trna synthetases
AU2003234600A1 (en) 2002-05-13 2003-11-11 Rigel Pharmaceuticals, Inc. tRNA SYNTHASE: MODULATORS OF ANGIOGENESIS
EP1923464A1 (en) 2002-08-30 2008-05-21 Japan Science and Technology Agency Ligase of a hyperthermostable bacterium and chip using the same
AU2003260786B2 (en) 2002-09-06 2008-03-13 Isogenica Limited In vitro peptide expression libraray
KR100575251B1 (ko) 2003-03-03 2006-05-02 재단법인서울대학교산학협력재단 ｐ38／ＪＴＶ－1을 유효성분으로 하는 암 치료용 약학적조성물 및 암 치료용 약학적 조성물의 스크리닝 방법
WO2004087875A2 (en) 2003-03-25 2004-10-14 Incyte Corporation Nucleic acid-associated proteins
WO2005009336A2 (en) 2003-05-01 2005-02-03 Replidyne, Inc. Antibacterial methods and compositions
EP1704242A4 (en) 2003-07-07 2008-06-18 Scripps Research Inst COMPOSITIONS WITH PAIRS OF ORTHOGONAL LEUCYL-TRNA AND AMINOACYL-TRNA-SYNTHETASE AND USES THEREOF
WO2005019415A2 (en) 2003-07-07 2005-03-03 The Scripps Research Institute Compositions of orthogonal lysyl-trna and aminoacyl-trna synthetase pairs and uses thereof
KR100599454B1 (ko) 2004-04-27 2006-07-12 재단법인서울대학교산학협력재단 종양 억제자로 작용하는 ａｉｍ3의 신규 용도
MXPA06014092A (es) 2004-06-04 2007-03-15 Scripps Research Inst Composiciones y metodos para el tratamiento de enfermedades neovasculares.
US20060079673A1 (en) 2004-08-02 2006-04-13 Paul Glidden Polynucleotides encoding tRNA synthetase fragments and uses thereof
US20060024288A1 (en) 2004-08-02 2006-02-02 Pfizer Inc. tRNA synthetase fragments
US20060078553A1 (en) 2004-10-07 2006-04-13 Paul Glidden Diverse multi-unit complexes including a tRNA synthetase fragment
US8282921B2 (en) 2004-08-02 2012-10-09 Paul Glidden tRNA synthetase fragments
US8003780B2 (en) 2004-11-24 2011-08-23 Neomics Co., Ltd. AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2
US7459529B2 (en) 2004-11-24 2008-12-02 Seoul National University Industry Foundation AIMP2-DX2 and its uses
JP4990792B2 (ja) 2004-12-22 2012-08-01 アンブレツクス・インコーポレイテツド アミノアシル−ｔＲＮＡシンテターゼの組成物およびこの使用
CA2594557C (en) 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
WO2007021297A1 (en) 2005-08-18 2007-02-22 Ambrx, Inc. COMPOSITIONS OF tRNA AND USES THEREOF
US7514229B2 (en) 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
WO2007064941A2 (en) 2005-12-02 2007-06-07 The Scripps Research Institute Angiogenic tyrosyl trna synthetase compositions and methods
AU2007224019A1 (en) 2006-03-03 2007-09-13 California Institute Of Technology Site-specific incorporation of amino acids into molecules
ZA200810836B (en) 2006-05-26 2010-07-28 Obodies Ltd OB fold domains
EP2052088A2 (en) 2006-08-02 2009-04-29 Genizon Biosciences Genemap of the human genes associated with psoriasis
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
CN101528914B (zh) 2006-09-08 2014-12-03 Ambrx公司 通过脊椎动物细胞位点特异性并入非天然氨基酸
CN103351437A (zh) 2006-11-17 2013-10-16 诺瓦提斯公司 Lingo结合分子及其制药用途
JP2010525362A (ja) 2007-04-27 2010-07-22 アイマジーン カンパニー リミテッド 免疫調節剤のスクリーニング方法
JP2009017840A (ja) 2007-07-13 2009-01-29 Japan Agengy For Marine-Earth Science & Technology 外来遺伝子を細胞に安定に保持する方法
EP2220218A4 (en) 2007-11-02 2010-12-08 Scripps Research Inst GENETICALLY ENCODED BORONATE AMINO ACID
JP5585904B2 (ja) 2008-02-08 2014-09-10 独立行政法人理化学研究所 アミノアシルｔＲＮＡ合成酵素活性を有するポリペプチド及びその利用
CA2718153A1 (en) 2008-03-11 2009-09-17 University Of North Carolina At Chapel Hill Angiostatic compositions comprising truncated tyrosyl-trna synthetase polypeptides and methods of using same
CN102105164A (zh) 2008-06-11 2011-06-22 Atyr医药公司 酪氨酰-trna合成酶多肽的血小板生成活性
EP2310498A1 (en) 2008-06-26 2011-04-20 Atyr Pharma, Inc. Compositions and methods comprising glycyl-trna synthetases having non-canonical biological activities
AU2008360729A1 (en) 2008-08-18 2010-02-25 Seoul National University Industry Foundation Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl tRNA synthetase
KR101067817B1 (ko) 2008-10-10 2011-09-27 서울대학교산학협력단 Ａｉｍｐ1 폴리펩티드에 대한 항체를 포함하는 관절염 진단용 조성물
KR101102485B1 (ko) 2008-10-10 2012-01-05 서울대학교산학협력단 Ｇｒｓ단백질 또는 이의 단편의 신규한 용도
KR101067815B1 (ko) 2009-02-05 2011-09-27 서울대학교산학협력단 제1형 당뇨병의 신규한 진단 마커
US20120058133A1 (en) 2009-02-19 2012-03-08 President And Fellows Of Harvard College Inhibition of trna synthetases and therapeutic applications thereof
ES2552773T3 (es) 2009-02-27 2015-12-02 Atyr Pharma, Inc. Motivos estructurales de polipéptidos asociados con la actividad de señalización celular
JP5730280B2 (ja) 2009-03-16 2015-06-03 パング バイオファーマ リミテッド 非カノニカル生物学的活性を有するヒスチジル−ｔＲＮＡシンテターゼスプライスバリアントを含む組成物および方法
WO2010120509A2 (en) 2009-03-31 2010-10-21 Atyr Pharma, Inc. Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities
US20110150885A1 (en) 2009-12-11 2011-06-23 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
ES2535951T3 (es) 2009-12-11 2015-05-19 Atyr Pharma, Inc. Histidil ARNt sintetasas para reducir la inflamación
US8828395B2 (en) 2009-12-11 2014-09-09 Atyr Pharma, Inc. Antibodies that bind tyrosyl-tRNA synthetases
US8828685B2 (en) 2010-02-04 2014-09-09 The Scripps Research Institute Monomeric forms of human aminoacyl-t-RNA synthetases having non-canonical biological activities
CA2797093C (en) 2010-04-26 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
CA2797259C (en) 2010-04-27 2020-09-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl trna synthetases
CA2797362C (en) 2010-04-27 2020-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
US8986680B2 (en) 2010-04-29 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
EP2563383B1 (en) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
CN103140233B (zh) 2010-05-03 2017-04-05 Atyr 医药公司 与甲硫氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
AU2011248357B2 (en) 2010-05-03 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases
WO2011139986A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
CA2797977C (en) 2010-05-03 2019-08-20 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
US9062301B2 (en) 2010-05-04 2015-06-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-tRNA synthetases
EP2566499B1 (en) 2010-05-04 2017-01-25 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
CA2799197C (en) 2010-05-14 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
US9034598B2 (en) 2010-05-17 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
AU2011258106B2 (en) 2010-05-27 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
CN103118694B (zh) 2010-06-01 2016-08-03 Atyr医药公司 与赖氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
CA2804278C (en) 2010-07-12 2021-07-13 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases
EP2593126B1 (en) 2010-07-12 2017-09-20 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
JP6116479B2 (ja) 2010-07-12 2017-04-19 エータイアー ファーマ， インコーポレイテッド グリシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
JP5964304B2 (ja) 2010-08-25 2016-08-03 エータイアー ファーマ， インコーポレイテッド チロシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CA2812795C (en) 2010-10-06 2021-08-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl trna synthetases
US20160144003A1 (en) 2011-05-19 2016-05-26 The Scripps Research Institute Compositions and methods for treating charcot-marie-tooth diseases and related neuronal diseases
WO2013022982A2 (en) 2011-08-09 2013-02-14 Atyr Pharma, Inc. Pegylated tyrosyl-trna synthetase polypeptides
US9816084B2 (en) 2011-12-06 2017-11-14 Atyr Pharma, Inc. Aspartyl-tRNA synthetases
WO2013086228A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Pegylated aspartyl-trna synthetase polypeptides
CN104220461A (zh) 2011-12-29 2014-12-17 Atyr医药公司 天冬氨酰-tRNA合成酶-FC缀合物
EP2814514B1 (en) 2012-02-16 2017-09-13 Atyr Pharma, Inc. Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
US20140066321A1 (en) 2012-07-23 2014-03-06 Pangu Biopharma Limited Structures of human histidyl-trna synthetase and methods of use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1352242A (zh) * 2000-11-02 2002-06-05 上海博德基因开发有限公司 一种新的多肽——人谷氨酰tRNA合成酶12.65和编码这种多肽的多核苷酸
US7248971B1 (en) * 2000-11-14 2007-07-24 International Business Machines Corporation Method and apparatus for discovering patterns in a set of sequences
WO2004087730A2 (en) * 2003-03-27 2004-10-14 The Johns Hopkins University Method for producing diverse libraries of encoded polymers
US20050136513A1 (en) * 2003-12-18 2005-06-23 The Scripps Research Institute Selective incorporation of 5-hydroxytryptophan into proteins in mammalian cells
CN102239253A (zh) * 2008-12-03 2011-11-09 普罗蒂亚维仕尼科技有限公司 谷氨酰tRNA合成酶（GtS）片段

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JIE JIA, ET AL.: "WHEP Domains direct noncanonical function of glutamyl-prolyl tRNA synthetase in translational control of gene expression", 《MOLECULAR CELL》 *
PRABHA SAMPATH, ET AL.: "Noncanonical function of gultamyl-prolyl-tRNA synthetase:gene-specific silencing of translation", 《CELL》 *
SANG GYU PARK, ET AL.: "Aminoacyl tRNA synthetases and their connections to disease", 《PNAS》 *
SHU MEI TING, ET AL.: "Isolation of Prolyl-tRNA synthetase as a free form and as a form associated with Glutamyl-tRNA synthetase", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *
STRAUSBERG,R. L.,ET AL.: "EPRS protein, partial[Homo sapiens]", 《GENBANK:AAH46156.1》 *
文圣梅: "谷氨酰-脯氨酰-tRNA合成酶（EPRS）结构与功能的新认识", 《军事医学科学院院刊》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110234757A (zh) * 2016-08-23 2019-09-13 韩国生命工学研究院 包含eprs蛋白或其片段的抗rna病毒组合物
CN110234757B (zh) * 2016-08-23 2023-05-16 韩国生命工学研究院 包含eprs蛋白或其片段的抗rna病毒组合物

Also Published As

Publication number Publication date
US20170240650A1 (en) 2017-08-24
AU2011248100A1 (en) 2012-12-13
EP2566492B1 (en) 2016-10-26
JP6008843B2 (ja) 2016-10-19
AU2011248100A9 (en) 2017-02-23
WO2011140266A2 (en) 2011-11-10
CA2798301C (en) 2020-09-15
US9062301B2 (en) 2015-06-23
JP2016041710A (ja) 2016-03-31
US10160814B2 (en) 2018-12-25
JP2013531478A (ja) 2013-08-08
WO2011140266A3 (en) 2012-03-29
US9574187B2 (en) 2017-02-21
CA2798301A1 (en) 2011-11-10
US20130224173A1 (en) 2013-08-29
AU2011248100B2 (en) 2017-01-19
EP2566492A4 (en) 2013-12-11
EP2566492A2 (en) 2013-03-13
US20150353915A1 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
CN103118692A (zh) 与半胱氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103096914A (zh) 与亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103140233A (zh) 与甲硫氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103096913A (zh) 与谷氨酰胺酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103124561A (zh) 与天冬氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103096911A (zh) 与异亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103096910A (zh) 与苏氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103118694A (zh) 与赖氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103108650A (zh) 与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN102985103A (zh) 与p38多-tRNA合成酶复合物相关的治疗、诊断和抗体组合物的创新发现
CN103118695A (zh) 与甘氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103118696B (zh) 与色氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物
CN103097524B (zh) 与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
JP6008840B2 (ja) フェニルアラニルαｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP5991963B2 (ja) バリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP6008838B2 (ja) アスパラギニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CN103200953B (zh) 与苯丙氨酰‑β‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103108649B (zh) 与组氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物
JP2017165779A (ja) セリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CN103096925A (zh) 与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130508